RO4929097 | ≥99%(HPLC) | Selleck | Gamma-secretase inhibitor
A summary of the clinical trials based on passive γ-secretase... | Download Table
Frontiers | DAPT, a γ-Secretase Inhibitor, Suppresses Tumorigenesis, and Progression of Growth Hormone-Producing Adenomas by Targeting Notch Signaling | Oncology
Making the final cut: pathogenic amyloid-β peptide generation by γ-secretase
Turning the tide on Alzheimer's disease: modulation of γ-secretase | Cell & Bioscience | Full Text
g-Secretase inhibitors in clinical development for the treatment of... | Download Table
Frontiers | Targeting Amyloidogenic Processing of APP in Alzheimer's Disease | Molecular Neuroscience
Gamma Secretase Inhibitors in Cancer: A Current Perspective on Clinical Performance - McCaw - 2021 - The Oncologist - Wiley Online Library
γ‐Secretase inhibitors in cancer clinical trials are pharmacologically and functionally distinct | EMBO Molecular Medicine
Chemical structure of γ-secretase inhibitors | Download Table
γ‐Secretase inhibitors in cancer clinical trials are pharmacologically and functionally distinct | EMBO Molecular Medicine
Recent developments of small molecule γ-secretase modulators for Alzheimer's disease - RSC Medicinal Chemistry (RSC Publishing)
Pharmaceuticals | Free Full-Text | BACE-1 and γ-Secretase as Therapeutic Targets for Alzheimer's Disease | HTML
Semagacestat Is a Pseudo-Inhibitor of γ-Secretase - ScienceDirect
γ-secretase inhibitors, DAPT and RO4929097, promote the migration of Human Glioma Cells via Smad5-downregulated E-cadherin Expression
Semagacestat – Gamma Secretase Inhibitor for Alzheimer's Disease - Clinical Trials Arena
Making the final cut: pathogenic amyloid-β peptide generation by γ-secretase
Clinical trials employing γ-secretase inhibitors in the treatment of... | Download Scientific Diagram
PDF) Three cases of apparent Vasogenic Edema (VE) from a phase 2 clinical trial of the gamma secretase Inhibitor BMS-708163 in patients with mild-to-moderate AD | Mark Meadowcroft and charles e albright -
Gamma-Secretase Inhibitor (DAPT), a potential therapeutic target drug, caused neurotoxicity in planarian regeneration by inhibiting Notch signaling pathway - ScienceDirect
